OKUR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.39%, SMA50 -4.23%, SMA200 -0.96%). The stock’s 14-day RSI is 51.35 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.5% below its high and over 56.47% above its low. Average 10-day trading volume of 194.93 thousand shares is significantly above the 3-month average of 107.76 thousand, indicating heightened recent market interest.

OnKure Therapeutics, Inc. generated EPS of -$6.17 over the past year. Five-year average earnings growth is 5.08%. Wall Street analysts project EPS growth of 41.07% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $34.00 to $30.00. The high target offers 1014.75% upside. The low target suggests 883.61% downside. The mean target is $32.67. This offers 971.15% upside. OnKure Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -9.17%. The prior quarter beat by -7.32%. Over the last six quarters, Apple has recorded several small beats. These include 60.0% in August 13, 2024.

OnKure Therapeutics, Inc. (NASDAQ:OKUR) closed at $3.05 USD, losing -$0.11 (-3.48%) from the previous close of $3.16. The stock is currently mid-range between its 52-week high and low $1.70 and $5.32. With a market capitalization of about $41.32 million, OnKure Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 103.53 thousand shares, trading with heavier-than-usual volume. Headquartered in Boulder, CO, OnKure Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Nicholas A. Saccomano, the company employs approximately 46 people and listed since April 08, 2021. OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.

OnKure Therapeutics, Inc. has 12.84 million shares outstanding. The public float is 5.81 million shares, elevated short interest at 2.38% of float. This equals 225.95 thousand shares. The short ratio is 3.23 days. Institutional investors hold 88.6% of the float. Insiders own 1.66%. ACORN BIOVENTURES, L.P. holds 1.13 million shares, Leverone Jason A. has 16.30 thousand shares and Saccomano Nicholas A has 7.42 thousand shares. Over the past six months, insider transactions show net selling. They sold 780.00 shares across 4 transactions.

OnKure Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.22. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that OnKure Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.56%, with price expected at $3.25 by March 20, 2026, within a range of $3.12 to $3.36 3-Month Outlook: Projected rise of 115.08%, reaching $6.56 by June 04, 2026, with a range of $5.91 to $6.97. 1-Year Outlook: Projected loss of -22.95%, with price at $2.35 by March 05, 2027, within a range of $0.00 to $1.15.

OnKure Therapeutics, Inc. (NASDAQ:OKUR) shares are flat 2.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows OnKure Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $34.00, suggesting 1014.75% upside. Our AI forecast model points to short-term strength (6.56% over two weeks), a medium-term rise (115.08% over three months), and a longer-term loss (-22.95% over one year), with expected trading ranges indicating moderate volatility.

OnKure Therapeutics, Inc. trades at a P/E ratio of -0.51, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.62 suggesting the stock is closer to book value. The P/FCF stands at -0.68, also below market averages.